2021
DOI: 10.2147/ott.s305388
|View full text |Cite
|
Sign up to set email alerts
|

Silencing HIPPI Suppresses Tumor Progression in Non-Small-Cell Lung Cancer by Inhibiting DNA Replication

Abstract: Introduction Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 80%–85% of all cases of lung cancer. Huntingtin interacting protein-1 interacting protein (HIPPI) is a transcription regulator and plays an important role in apoptotic cell death. However, the role of HIPPI in NSCLC remains unclear. Methods Immunohistochemistry (IHC) and qRT-PCR were performed for expression analysis. The roles of HIPPI were studied using… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 31 publications
0
4
0
Order By: Relevance
“… 97 , 98 Non-small cell lung cancer He et al and Xie et al. 83 , 99 He et al. 83 Lymphoma Braggio et al and Sung et al.…”
Section: Resultsmentioning
confidence: 99%
“… 97 , 98 Non-small cell lung cancer He et al and Xie et al. 83 , 99 He et al. 83 Lymphoma Braggio et al and Sung et al.…”
Section: Resultsmentioning
confidence: 99%
“…IHC staining was performed as described previously ( 34 ). Briefly, the tissue slices underwent deparaffinization, followed by antigen retrieval in 5 mM Tris-HCl for 10 mins using microwave pretreatment.…”
Section: Methodsmentioning
confidence: 99%
“…demonstrated that simvastatin combines with tamoxifen impaired breast cancer cell proliferation and resulted in apoptosis in vivo and in vitro. Knockout of MCM8 or MCM9 selectively increases cisplatin sensitivity in specific cancer cells such as HCT116 and HeLa cells 331,332 . However, siRNA‐mediated MCM8 silencing could not alter the cisplatin sensitivity of normal HFF2/T fibroblasts, indicating MCM8 may act as a molecular target just in cancer cells.…”
Section: Dna Replication Disease and Therapymentioning
confidence: 99%
“…Knockout of MCM8 or MCM9 selectively increases cisplatin sensitivity in specific cancer cells such as HCT116 and HeLa cells. 331 , 332 However, siRNA‐mediated MCM8 silencing could not alter the cisplatin sensitivity of normal HFF2/T fibroblasts, indicating MCM8 may act as a molecular target just in cancer cells. Consistent with cisplatin, silencing MCM8 and MCM9 selectively hypersensitizes cancer cells to Olaparib, which may rely on MCM8‐9's role in resolving RS.…”
Section: Dna Replication Disease and Therapymentioning
confidence: 99%